
Henrik Zetterberg
Articles
-
1 month ago |
alzres.biomedcentral.com | Frederikke Kragh |Mathias Holsey |Anja Hviid |Steen Gregers |Mathias Holsey Gramkow |Anja Hviid Simonsen | +8 more
Correction: Short‑term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort Correction Open access Published: 21 May 2025 Alzheimer's Research & Therapy volume 17, Article number: 110 (2025) Cite this article The Original Article was published on 21 January 2025 Correction: Alz Res Therapy 17, 26 (2025)Following publication of the original article [1], the coloured lines legend (red AD, blue nonAD) to Fig.
-
Dec 30, 2024 |
alzres.biomedcentral.com | Maxime Van Egroo |Elise Beckers |Nicholas Ashton |Kaj Blennow |Henrik Zetterberg
ReferencesVan Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, et al. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease. Sleep. 2019;42:1–13. Google Scholar Rigat L, Ouk K, Kramer A, Priller J. Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer’s disease. Acta Physiol. 2023;238:1–13. Google Scholar Winer JR, Morehouse A, Fenton L, Harrison TM, Ayangma L, Reed M, et al.
-
Dec 23, 2024 |
alzres.biomedcentral.com | Georgette Argiris |Muge Akinci |Cleofé Peña-Gómez |Eleni Palpatzis |Marina García-Prat |Mahnaz Shekari | +8 more
ReferencesJack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Article PubMed Google Scholar Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.
-
Nov 17, 2024 |
nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more
AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.
-
Nov 17, 2024 |
nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more
AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →